Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with sickle cell disease
Hydroxyurea showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · premenopausal women (ages 18–36 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · premenopausal women (age 18−47.3 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Serious adverse events · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Serious adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review